{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:59:43Z","timestamp":1790683183346,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40272-026-00768-z","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:29:19Z","timestamp":1787048959000},"page":"575-580","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["AFREZZA\u00ae (Insulin Human) Inhalation Powder: Pediatric First Approval"],"prefix":"10.1007","volume":"28","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"issue":"1 Suppl","key":"768_CR1","first-page":"43s","volume":"28","author":"LM Laffel","year":"2026","unstructured":"Laffel LM, Valent AM. Potential role of inhaled insulin in the management of gestational diabetes mellitus and pediatric type 1 diabetes. Diabetes Technol Ther. 2026;28(1 Suppl):43s\u201354s.","journal-title":"Diabetes Technol Ther"},{"issue":"1 Suppl","key":"768_CR2","first-page":"26S","volume":"28","author":"CJ Levy","year":"2026","unstructured":"Levy CJ, Seaquist E. Impact of inhaled insulin therapy on hypoglycemia. Diabetes Technol Ther. 2026;28(1 Suppl):26S\u201330S.","journal-title":"Diabetes Technol Ther"},{"issue":"14","key":"768_CR3","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1007\/s40265-015-0472-0","volume":"75","author":"ES Kim","year":"2015","unstructured":"Kim ES, Plosker GL. AFREZZA\u00ae (insulin human) inhalation powder: a review in diabetes mellitus. Drugs. 2015;75(14):1679\u201386.","journal-title":"Drugs"},{"key":"768_CR4","unstructured":"Mannkind Corporation. MannKind announces FDA approval of Afrezza\u00ae, the first and only inhaled mealtime insulin for use in children and adolescents aged 6 and older living with diabetes [media release]. 29 May 2026. https:\/\/mannkindcorp.com\/."},{"key":"768_CR5","unstructured":"MannKind Corporation. AFREZZA\u00ae (insulin human) inhalation powder, for oral inhalation use: US prescribing information. 2026. https:\/\/www.fda.gov\/. Accessed 9 June 2026."},{"key":"768_CR6","unstructured":"Mannkind Corporation. MannKind Corporation announces FDA approval of AFREZZA(R); a novel, rapid-acting inhaled insulin for the treatment of diabetes [media release]. 27 June 2014. https:\/\/mannkindcorp.com\/."},{"issue":"1 Suppl","key":"768_CR7","first-page":"38S","volume":"28","author":"E Cengiz","year":"2026","unstructured":"Cengiz E, Beck RW. Use of inhaled insulin with automated insulin delivery systems. Diabetes Technol Ther. 2026;28(1 Suppl):38S\u201342S.","journal-title":"Diabetes Technol Ther"},{"issue":"1 Suppl","key":"768_CR8","first-page":"8S","volume":"28","author":"SV Edelman","year":"2026","unstructured":"Edelman SV, Blevins TC, Parkin CG, et al. Dosing Afrezza: it\u2019s not that complicated. Diabetes Technol Ther. 2026;28(1 Suppl):8S\u201313S.","journal-title":"Diabetes Technol Ther"},{"issue":"3","key":"768_CR9","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s13300-023-01368-7","volume":"14","author":"MJ Haller","year":"2023","unstructured":"Haller MJ, Jones MC, Bhavsar S, et al. Time-action profile of Technosphere insulin in children with type 1 diabetes. Diabetes Ther. 2023;14(3):611\u20137.","journal-title":"Diabetes Ther."},{"issue":"1","key":"768_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2337\/dc25-1994","volume":"49","author":"MJ Haller","year":"2026","unstructured":"Haller MJ, Kanapka L, Monzavi R, et al. INHALE-1: a multicenter randomized trial of inhaled Technosphere insulin in children with type 1 diabetes. Diabetes Care. 2026;49(1):179\u201387.","journal-title":"Diabetes Care"},{"key":"768_CR11","doi-asserted-by":"crossref","unstructured":"Kaiserman K, Sylvan J, Mycue LE, et al. Efficacy and safety of inhaled Technosphere insulin (TI) vs. rapid-acting analog in youth with HbA1c \u22649.5%: subgroup analysis from INHALE-1 [abstract no. 1741-P]. Diabetes. 2026;75(Suppl 1).","DOI":"10.2337\/db26-1741-P"},{"key":"768_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/15209156261432138","author":"L Ekhlaspour","year":"2026","unstructured":"Ekhlaspour L, Kanapka L, Dewan A, et al. Inhaled Technosphere insulin reduces postmeal glucose excursion in youth living with type 1 diabetes. Diabetes Technol Ther. 2026. https:\/\/doi.org\/10.1177\/15209156261432138.","journal-title":"Diabetes Technol Ther"},{"key":"768_CR13","doi-asserted-by":"crossref","unstructured":"Beck RW, Kanapka L, Monzavi R, et al. Inhaled Technosphere insulin in children with diabetes: the INHALE-1 extension study. Diabetes Technol Ther. 2026;28(8):772\u201381.","DOI":"10.1177\/15209156261420176"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00768-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-026-00768-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00768-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:17:07Z","timestamp":1790680627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-026-00768-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["768"],"URL":"https:\/\/doi.org\/10.1007\/s40272-026-00768-z","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"23 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sheridan M. Hoy is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}